Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
TRThe rgp120 HIV Vaccine Study Group
University of California Davis Medical Center
Indexed incrossrefpubmed
Abstract
Background
A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection.
Methods
A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women at high risk for heterosexual transmission of HIV-1. Volunteers received 7 injections of either vaccine or placebo (ratio, 2 : 1) over 30 months. The primary end point was HIV-1 seroconversion over 36 months.
Citation impact
936
total citations
- FWCI
- 14.34
- Percentile
- 100%
- References
- 46
Citations per year
Authors
1- TRThe rgp120 HIV Vaccine Study GroupCorresponding
University of California Davis Medical Center
Topics & keywords
Topics
Keywords
- Seroconversion
- Placebo
- Medicine
- Vaccine trial
- Recombinant DNA
- Internal medicine
- Human immunodeficiency virus (HIV)
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.